A limitation of our retrospective study is the evaluation of only three single‐gene assays (EGFR, ALK, and PD‐L1) during the study period, in comparison to the expanded range of actionable genomic alterations currently evaluated as standard‐of‐care practice in non‐squamous NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.